I n-hospital cardiac arrest (IHCA) is a relatively common and highly morbid event (1) . Advanced Cardiac Life Support (ACLS) providers commonly have access to a number of pharmacologic interventions and need to make quick decisions regarding medication administration. To assist with decision-making, the American Heart Association (AHA) publishes algorithms which can be used to guide resuscitative efforts (2) (3) (4) (5) . These algorithms are widely taught to ACLS providers and provide recommendations regarding the selection/ timing of certain medications (6) . To date, however, trends in IHCA drug administration remain unexplored, and usage of those medications not explicitly included in the cardiac arrest algorithms is largely unknown.
Updates to the AHA guidelines in 2000, 2005, 2010 , and 2015 have included modifications to drug administration recommendations. In the most recent 2015 recommendations, for instance, vasopressin was removed from the ACLS algorithm to increase simplicity (3) . Atropine was removed from the pulseless electrical activity (PEA) and asystole guidelines in 2010 (4) . Amiodarone was introduced as a first-line antiarrhythmic for shock-refractory ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT) in 2000 (5) . Delays in guideline implementation are well described and may be associated with preventable harm (7) . Given the common requirement that acute care providers receive standardized training/ certification in ACLS (6, 8) , there is a unique opportunity to study the impact of this dissemination model on the assimilation of society guidelines into practice.
In the present study, we leverage the AHA Get With The Guidelines Resuscitation (GWTG-R) database to investigate trends in IHCA drug administration. We additionally seek to understand how updates to the AHA ACLS algorithm impact medication prescribing patterns, as this may shed light on the effectiveness of the ACLS training model. Finally, we aim to describe the use of medications not incorporated into the AHA ACLS algorithms, so as to better direct research and educational initiatives.
MATERIALS AND METHODS

Data Source
The GWTG-R database is a large, prospectively collected, quality-improvement registry of IHCA events sponsored by the AHA. Hospitals participating in the registry submit clinical information and outcomes for consecutive patients using an online Patient Management Tool (Quintiles, Cambridge, MA). The design, data collection, and quality control of the repository have been described previously (9, 10) . Data are collected prospectively on all IHCAs who do not have prior do-notresuscitate orders.
This research was classified as nonhuman research by the Beth Israel Deaconess Medical Center Institutional Review Board.
Study Population
Index adult IHCA events in the GWTG-R database were included. Events from the years 2000 (the year of the start of the registry) and 2017 (for which data entry was ongoing at the time of analysis), events listed as occurring in a pediatric area, events missing hospital-level information, and events without chest compressions were excluded.
Medication Exposures and Definitions
The GWTG-R database includes medications provided following pulselessness and prior to return of spontaneous circulation (ROSC) or death. These medications include epinephrine, vasopressin, amiodarone, lidocaine, calcium, magnesium, atropine, dextrose, and bicarbonate. Timing of drug administration is only collected for epinephrine and vasopressin. Shockable rhythm is defined as pulseless VT/VF, and nonshockable rhythm is defined as PEA or asystole.
Updates to AHA ACLS Guidelines and Prescribing Patterns
We hypothesized that changes to the AHA ACLS algorithms would have an effect on medication prescribing patterns in the year following guideline update. Specifically, we a priori planned to assess changes in atropine use after 2010 and vasopressin use after 2015. These time points and medications were selected to reflect major deletions from the algorithm.
Statistical Analysis
Descriptive statistics were used to characterize the study population. Continuous variables are reported as medians with interquartile ranges (IQRs). Categorical variables are reported as counts with frequencies. Rates of use for each medication were calculated for each year and then presented graphically over time.
For each of the above medications of interest, multivariable logistic regression with generalized estimating equations (GEEs) and an exchangeable variance-covariance structure was used to assess the relationship between event year and medication. For these analyses, year was considered as a categorical variable (2001 used as a reference). Covariates in the GEE model, chosen by the authors as those most likely to be associated with prescribing patterns, are listed in Table e1 (Supplemental Digital Content 1, http://links.lww.com/CCM/ E167) (for variable definitions, see Table e2 , Supplemental Digital Content 1, http://links.lww.com/CCM/E167).
To assess the effect of guideline updates on atropine prescribing patterns, we performed interrupted time series analyses using segmented linear regression with GEE. For large datasets, linear regression is valid even for binary outcomes and often provides more easily interpretable results (11) . The model included all covariables described above, in addition to variables estimating the preintervention trend, change in level following the intervention, and the postintervention trend. To reflect the timing of the updated guideline publication in October 2010, the preintervention time included all of the year 2010 (4). As our cohort only included 1 year after 2015, segmented regression could not be performed to assess changes in vasopressin use. Instead, the reference year in the multivariable GEE was changed to 2015, and the annual adjusted odds ratio (aOR) for receiving vasopressin was assessed with respect to the updated reference year.
Events in which data were missing for any of the included covariates were excluded (22.1% of all cases) ( Table e3 , Supplemental Digital Content 1, http://links.lww.com/CCM/ E167). As a sensitivity analysis, multiple imputation was performed using chained equations and under the assumption that data were missing at random. A total of 20 unique datasets were created and the models recreated in each dataset. The results for each model were then combined across datasets. As not all hospitals contributed data throughout the study period, unadjusted trends in medication use were also assessed in post hoc sensitivity analyses wherein the cohort was limited to only those hospitals contributing data on at least five IHCAs per year throughout the study period. p values less than 0.05 were considered statistically significant. All statistics were performed using STATA, Version 14 (StataCorp LP, College Station, TX).
RESULTS
Study Population
A total of 268,031 IHCA events occurring in 712 hospitals were included ( Fig. 1 for cohort (Fig. 2B) .
Vasopressin was used in 27,487 arrests (10.3%), including 4,203 arrests (9.5%) with an initial shockable rhythm and 21,666 arrests (10.8%) with an initial nonshockable rhythm. Use of vasopressin increased between 2001 and 2007 then largely remained stable until rates of use declined in 2015 and 2016 ( Fig. 2A) . Using 2015 as the reference year, odds of vasopressin use were lower in 2016 (aOR, 0.38; 95% CI, 0.33-0.45; p < 0.0001) (Fig. 2B) . (Fig. 3A) . After multivariable adjustment, patients in 2016 had greater odds of receiving amiodarone during their arrest than patients in 2001 (aOR, 3.39; 95% CI, 2.90-3.96; p < 0.0001) (Fig. 3B) .
Antiarrhythmics
Lidocaine was used in 19,423 arrests (7.2%), including 9,863 arrests (22.2%) with an initial shockable rhythm and 8,521 (4.3%) with an initial nonshockable rhythm. The rate of lidocaine use decreased over time between 2001 and 2016 (Fig. 3A) . After multivariable adjustment, patients in 2016 had lower odds of receiving lidocaine during their arrest as compared to patients in 2001 (aOR, 0.19; 95% CI, 0.16-0.22; p < 0.0001) (Fig. 3B) .
Atropine
Atropine was used in 139,332 arrests (52.0%), including 16,488 (37.1%) with an initial shockable rhythm and 112,826 (56.4%) with an initial nonshockable rhythm. Rates of atropine use were similar between 2001 and 2010 before declining between 2011 and 2016 (Fig. 4A) . After multivariable adjustment, patients in 2016 had lower odds of receiving atropine during their arrest as compared to patients in 2001 (aOR, 0.07; 95% CI, 0.06-0.08; p < 0.0001) (Fig. 4B) . In the interrupted time series analysis, there was a downward step change in the intercept and downward slope change when comparing the pre-and postintervention period in both those with an initial shockable rhythm (intercept change 26.1%; 95% CI, 20-32.7%; p < 0.0001 and slope change, 3.1%/yr; 95% CI, 2.8-3.4%; p < 0.0001) and those with an initial nonshockable rhythm (intercept change, 23.6%; 95% CI, 19.5-27.7%; p < 0.0001 and slope change 7.3%/yr; 95% CI, 6.7-7.6%; p < 0.0001) (Fig. e2 , Supplemental Digital Content 1, http://links.lww.com/CCM/ E167). This finding persisted after adjustment (p < 0.0001) and was similar when quarterly time intervals were used in place of years (Fig. e3 , Supplemental Digital Content 1, http://links. lww.com/CCM/E167). 
Electrolytes and Others
The rates of use of bicarbonate, calcium, magnesium, and dextrose have all increased over time (Fig. 5A with rates of medication use stratified by initial rhythm). As compared to the year 2001, patients in the year 2016 had higher odds of receiving bicarbonate (aOR, 2.01; 95% CI, 1.77, 2.27; p < 0.0001), higher odds of receiving calcium (aOR, 1.99; 95% CI, 1.72-2.30; p < 0.0001), higher odds of receiving dextrose (aOR, 2.76; 95% CI, 2.25-3.39; p < 0.0001), and higher odds of receiving magnesium (aOR, 2.23; 95% CI, 1.89-2.65; p < 0.0001) (Fig. 5B) .
Results of analyses following multiple imputation are included in Table e4 (Supplemental Digital Content 1, http://links.lww. com/CCM/E167) and are similar to the complete case analysis. When restricting the analysis to hospitals providing data for the entire period (n = 27,081 from 21 sites), trends in medication use were consistent with those in the full cohort (Figs. e4-e7 , Supplemental Digital Content 1, http://links.lww.com/CCM/ E167). The results of the segmented regression analysis for atropine were likewise similar to those in the full cohort, although the magnitude was reduced (Table e5, Supplemental Digital Content 1, http://links.lww.com/CCM/E167).
DISCUSSION
Temporal trends in medication use during IHCA have not been comprehensively described but are essential in order to evaluate current practice, better understand implementation science in resuscitation medicine, and guide future ACLS guideline updates. In this study, the use of epinephrine, amiodarone, bicarbonate, calcium, magnesium, and dextrose were found to have increased over time. The increased use of some medications comes despite shorter arrest durations. Lidocaine, atropine, and vasopressin have declined in use since 2001, 2010, and 2015, respectively. These findings are robust to multivariable adjustment controlling for hospital-, patient-, and arrest-level factors.
The AHA ACLS training model, with the near-universal requirement of hospital-based healthcare professionals in the United States participating in IHCA response to maintain certification biannually (6, 8, 12, 13) , allows for rapid dissemination of guideline updates. The effect of the ACLS training model on medication prescribing patterns is perhaps most saliently reflected by atropine use. Atropine was removed from the ACLS algorithm in 2010-not necessarily due to new highquality evidence of ineffectiveness/harm, but rather as a result of a review of existing literature (4) . Nevertheless, the proportion of patients receiving atropine declined substantially each year between 2011 and 2016 and fell nearly 50% within 2 years of the update. These results are similar to those seen in an outof-hospital cardiac arrest population (14) .
Further demonstrating the effect of guideline change on clinical practice, the proportion of patients receiving amiodarone increased by nearly 50% between 2001 and 2002 following the inclusion of amiodarone as a first-line treatment of shock-refractory VF and pulseless VT in 2000 (5) . Although data prior to 2001 were not included in the present study, the use of amiodarone was likely low given that intraarrest use was rarely reported until the late 1990s (15) (16) (17) (18) . The change in clinical practice is particularly notable given that the landmark study by Kudenchuk et al (18) was published in 1999, just 1 year prior to the ACLS update. Furthermore, amiodarone use steadily increased over time, whereas lidocaine use fell following stronger language in the guidelines favoring amiodarone over lidocaine (2, 4) and finally the removal of lidocaine from the VF/pulseless VT pictorial algorithm (although remained in the text) in 2010 (4) . The slower decline in lidocaine use after 2010, as compared to the decline in atropine use over the same period, may be due to a more gradual deemphasis of lidocaine in the guidelines and the continued presentation of lidocaine as an alternative to amiodarone in the guideline text. Vasopressin was introduced as part of the ACLS cardiac arrest algorithm in 2000, at which time it was thought that it "may be a more effective pressor agent than epinephrine." (5, (19) (20) (21) Our data show a consistent increase in vasopressin use after the 2000 update (5) . In 2005 and 2010, vasopressin was deemphasized in the ACLS algorithm and was removed in 2015 based on evidence showing no benefit over epinephrine and to limit complexity (22) (23) (24) (25) . These changes are again reflected in our data, with the proportion of patients receiving vasopressin falling from 10.9% in 2015 to 4.7% in 2016. It is notable, however, that vasopressin use began to decline a year prior to the 2015 guideline update, suggesting a potential role of external factors-including increases in medication cost (26) .
Although the AHA does not recommend the routine use of bicarbonate, calcium, and magnesium during ACLS outside of certain situations (e.g., magnesium in torsades de pointes) (2-5, 27, 28), our study found an increase in their use between 2001 and 2016. Bicarbonate was used in nearly 50% of all IHCAs in 2016. This is notable given recent bicarbonate shortages (29) . Dextrose use also rose despite evidence suggesting that the administration of dextrose during IHCA is associated with worse outcomes (30) . That use of bicarbonate, calcium, dextrose, and magnesium appears to be increasing over time may be related to the fact that these medications are not listed on the ACLS graphical algorithm (aside from magnesium in the 2005 VF/VT algorithm), that recommendations surrounding the use of these medications have not changed, and/or that there remain certain indications for their use (i.e., calcium for hyperkalemia). Understanding the situations in which these medications are being used during IHCA may be helpful in directing future research.
Delays in the implementation of clinical guidelines into routine patient care are well described in other medical fields, and longer delays may be associated with harm (7, 31, 32) . Resuscitation science, generally, is no exception with many investigators highlighting uneven implementation of new science (33) (34) (35) (36) . The data presented here arguably show a more rapid uptake of updated ACLS medication guideline recommendations into practice than might be expected. We hypothesize that this more rapid uptake is related to the AHA ACLS training model, and the quick decision-making required during IHCA which promotes an algorithmic response. Nevertheless, although ACLS guideline changes appear to have an effect on prescribing practices overall, some clinicians continue to use medications in ways that are not congruent with current guidelines. For instance, approximately 20% of patients with initial nonshockable rhythms received atropine in 2016. These findings may be related to individual interpretation of the existing literature as opposed to incomplete guideline penetration, but clearly there is a knowledge gap which could be addressed with a more granular approach (e.g., provider surveys) to studying prescribing patterns.
Our study was limited in that the GWTG-R registry only collects the initial recorded rhythm of each arrest and does not account for changes in rhythm during IHCA. In addition, we did not assess the relationship between drug administration and patient outcomes in this study due to lack of time-toadministration data for most medications and the related risk of bias (37) . Our analysis was limited to hospitals participating in GWTG-R, which may be more responsive to AHA guidelines and limits international generalizability. Discontinuous years of GWTG participation may have resulted in hospitallevel variation with respect to medication prescribing. Finally, we were unable to assess other factors that may have influenced the use of medications such as cost/availability.
CONCLUSIONS
Significant temporal variability exists in the use of various pharmacologic interventions during IHCA. Updates to AHA ACLS guidelines were associated with rapid and substantial changes to certain IHCA medication prescribing patterns. This information can be used to understand current practice and guide future AHA ACLS updates and implementation.
